Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs
Xconomy
JANUARY 31, 2020
million more shares than anticipated and pricing at the high end of its planned range. The stock price closed at $21.80, up 28 percent. In July 2018, the company licensed. Arcutis Biotherapeutics raised about $159 million from its IPO, offering 1.6 The Westlake Village, CA-based biotech sold about 9.4
Let's personalize your content